A Manifold prediction market indicates a 55.85% probability that Liang Mong-Song, a key engineer at SMIC, will leave...
A Manifold prediction market indicates a 55.85% probability that Liang Mong-Song, a key engineer at SMIC, will leave the company within the next 5 years (source). Separately, markets assign low probabilities (4-18%) to SMIC outcompeting TSMC by 2024-2033 (source, source, source) and only 11% chance of achieving 3nm before 2026 (source). While prediction markets are speculative, the high probability of losing a top engineer represents a concrete talent risk for SMIC, potentially weakening its ability to close the technology gap with TSMC. This is a low-confidence signal due to reliance on a single prediction platform rather than confirmed events.
confidence score
Strong evidence: 1 independent source class support this read.
0981.HK has already moved down -17% over the recent 30-90 day window.
signal brief
A Manifold prediction market indicates a 55.85% probability that Liang Mong-Song, a key engineer at SMIC, will leave the company within the next 5 years (source). Separately, markets assign low probabilities (4-18%) to SMIC outcompeting TSMC by 2024-2033 (source, source, source) and only 11% chance of achieving 3nm before 2026 (source). While prediction markets are speculative, the high probability of losing a top engineer represents a concrete talent risk for SMIC, potentially weakening its ability to close the technology gap with TSMC. This is a low-confidence signal due to reliance on a single prediction platform rather than confirmed events.
source data used
- https://manifold.markets/alby/will-chinas-smic-manage-to-manufact-49aa07abdea3
- https://manifold.markets/alby/will-chinas-smic-manage-to-manufact
- https://manifold.markets/alby/will-chinas-smic-manage-to-manufact-13a6f53950b0
- https://manifold.markets/ersatz/will-chinas-semiconductor-manufactu
- https://manifold.markets/GeorgeVii/will-liang-mongsong-work-at-a-semic
spillover entities
Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.